hrcak mascot   Srce   HID

Izvorni znanstveni članak

FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB (FCR) IN THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): UNIVERSITY HOSPITAL CENTRE ZAGREB EXPERIENCE

Ivan Krečak
Sandra Bašić-Kinda
Dino Dujmović
Ida Hude
Ivo Radman-Livaja
Klara Dubravčić
Koraljka Gjadrov Kuveždić
Ivana Ilić
Igor Aurer

Puni tekst: hrvatski, pdf (777 KB) str. 0-0 preuzimanja: 139* citiraj
APA 6th Edition
Krečak, I., Bašić-Kinda, S., Dujmović, D., Hude, I., Radman-Livaja, I., Dubravčić, K., ... Aurer, I. (2017). FLUDARABIN, CIKLOFOSFAMID I RITUKSIMAB (FCR) U LIJEČENJU BOLESNIKA S KRONIČNOM LIMFOCITNOM LEUKEMIJOM (KLL): ISKUSTVO KLINIČKOGA BOLNIČKOG CENTRA ZAGREB. Liječnički vjesnik, 139 (7-8), 0-0. Preuzeto s https://hrcak.srce.hr/189762
MLA 8th Edition
Krečak, Ivan, et al. "FLUDARABIN, CIKLOFOSFAMID I RITUKSIMAB (FCR) U LIJEČENJU BOLESNIKA S KRONIČNOM LIMFOCITNOM LEUKEMIJOM (KLL): ISKUSTVO KLINIČKOGA BOLNIČKOG CENTRA ZAGREB." Liječnički vjesnik, vol. 139, br. 7-8, 2017, str. 0-0. https://hrcak.srce.hr/189762. Citirano 16.07.2019.
Chicago 17th Edition
Krečak, Ivan, Sandra Bašić-Kinda, Dino Dujmović, Ida Hude, Ivo Radman-Livaja, Klara Dubravčić, Koraljka Gjadrov Kuveždić, Ivana Ilić i Igor Aurer. "FLUDARABIN, CIKLOFOSFAMID I RITUKSIMAB (FCR) U LIJEČENJU BOLESNIKA S KRONIČNOM LIMFOCITNOM LEUKEMIJOM (KLL): ISKUSTVO KLINIČKOGA BOLNIČKOG CENTRA ZAGREB." Liječnički vjesnik 139, br. 7-8 (2017): 0-0. https://hrcak.srce.hr/189762
Harvard
Krečak, I., et al. (2017). 'FLUDARABIN, CIKLOFOSFAMID I RITUKSIMAB (FCR) U LIJEČENJU BOLESNIKA S KRONIČNOM LIMFOCITNOM LEUKEMIJOM (KLL): ISKUSTVO KLINIČKOGA BOLNIČKOG CENTRA ZAGREB', Liječnički vjesnik, 139(7-8), str. 0-0. Preuzeto s: https://hrcak.srce.hr/189762 (Datum pristupa: 16.07.2019.)
Vancouver
Krečak I, Bašić-Kinda S, Dujmović D, Hude I, Radman-Livaja I, Dubravčić K i sur. FLUDARABIN, CIKLOFOSFAMID I RITUKSIMAB (FCR) U LIJEČENJU BOLESNIKA S KRONIČNOM LIMFOCITNOM LEUKEMIJOM (KLL): ISKUSTVO KLINIČKOGA BOLNIČKOG CENTRA ZAGREB. Liječnički vjesnik [Internet]. 2017 [pristupljeno 16.07.2019.];139(7-8):0-0. Dostupno na: https://hrcak.srce.hr/189762
IEEE
I. Krečak, et al., "FLUDARABIN, CIKLOFOSFAMID I RITUKSIMAB (FCR) U LIJEČENJU BOLESNIKA S KRONIČNOM LIMFOCITNOM LEUKEMIJOM (KLL): ISKUSTVO KLINIČKOGA BOLNIČKOG CENTRA ZAGREB", Liječnički vjesnik, vol.139, br. 7-8, str. 0-0, 2017. [Online]. Dostupno na: https://hrcak.srce.hr/189762. [Citirano: 16.07.2019.]

Sažetak
In clinical trials the combination of fludarabine, cyclophosphamide and rituximab (FCR) demonstrated superior results and became the gold standard for first-line treatment of fit patients with chronic lymphocytic leukemia (CLL). The aim of this study was to evaluate the efficacy, toxicity and feasibility of this protocol in everyday clinical practice. We ­retrospectively analyzed the outcomes of 43 CLL patients treated at the Division of Haematology, Department of Internal Medicine, University Hospital Centre Zagreb. The dosing of rituximab differed from that in clinical trials, we administered 375mg/m2 of rituximab per cycle, in previously untreated patients for eight and in relapsed/refractory patients for six cycles. The response rate was 95% with 83% of complete remissions. Twenty–nine patients received FCR as a front–line therapy; three-year overall and progression–free survival were 90% and 80%, respectively. In relapsed/refractory disease three–year overall and progression–free survival were 86% and 62%, respectively. Severe neutropenias occurred in 46% and serious infections in 9% of patients. According to these results, the toxicity profile and treatment outcomes in everyday routine clinical practice are similar to those reported in clinical trials.

Ključne riječi
Leukemia, lymphocytic, chronic, B-cell – complications, drug therapy; Vidarabine – administration and dosage, adverse effects, analogs and derivatives, therapeutic use; Cyclophosphamide – administration and dosage, adverse effects, therapeutic use; Rituximab – administration and dosage, adverse effects, therapeutic use; Antineoplastic agents – administration and dosage, adverse effects, therapeutic use; Antineoplastic combined chemotherapy protocols – administration and dosage, adverse effects, therapeutic use; Treatment outcome; Remission induction; Disease-free survival

Hrčak ID: 189762

URI
https://hrcak.srce.hr/189762

[hrvatski]

Posjeta: 333 *